Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432

被引：46

作者：

Aoki, Masatoshi ^{[1
,2
,3
,4
]}

Ueda, Shugo ^{[5
]}

Nishikawa, Hiroyoshi ^{[1
,2
]}

Kitano, Shigehisa ^{[3
]}

Hirayama, Michiko ^{[1
,2
]}

Ikeda, Hiroaki ^{[1
,2
]}

Toyoda, Hideki ^{[6
]}

Tanaka, Kyosuke ^{[6
]}

Kanai, Michiyuki ^{[5
]}

Takabayashi, Arimichi ^{[5
]}

Imai, Hiroshi ^{[7
]}

Shiraishi, Taizo ^{[7
]}

Sato, Eiichi ^{[8
]}

Wada, Hisashi ^{[9
]}

Nakayama, Eiichi ^{[10
]}

Takei, Yoshiyuki ^{[4
]}

Katayama, Naoyuki ^{[3
]}

Shiku, Hiroshi ^{[1
,2
]}

Kageyama, Shinichi ^{[1
,2
,3
]}

机构：

[1] Mie Univ, Grad Sch Med, Dept Canc Vaccine, Tsu, Mie 5148507, Japan

[2] Mie Univ, Grad Sch Med, Dept Immunogene Therapy, Tsu, Mie 5148507, Japan

[3] Mie Univ, Grad Sch Med, Dept Haematol & Oncol, Tsu, Mie 5148507, Japan

[4] Mie Univ, Grad Sch Med, Dept Gastroenterol, Tsu, Mie 5148507, Japan

[5] Kitano Hosp, Tazuke Kofukai Med Res Inst, Dept Gastroenterol Surg & Oncol, Osaka, Japan

[6] Mie Univ, Grad Sch Med, Dept Endoscop Med, Tsu, Mie 5148507, Japan

[7] Mie Univ, Grad Sch Med, Dept Pathol, Tsu, Mie 5148507, Japan

[8] Tokyo Med Univ, Dept Pathol, Tokyo, Japan

[9] Osaka Univ, Grad Sch Med, Dept Surg, Osaka, Japan

[10] Okayama Univ, Grad Sch Med, Dept Immunol, Okayama, Japan

来源：

VACCINE | 2009年 / 27卷 / 49期

关键词：

Antibody response; NY-ESO-1; HER2; HUMORAL IMMUNE-RESPONSES; SQUAMOUS-CELL CARCINOMA; HUMAN TUMOR-ANTIGENS; ESOPHAGEAL CANCER; DENDRITIC CELLS; EXPRESSION; PEPTIDE; IMMUNOTHERAPY; C-ERBB-2; COMPLEX;

D O I：

10.1016/j.vaccine.2009.09.018

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

071005 [微生物学]; 100108 [医学免疫学];

摘要：

Combination vaccines of the NY-ESC-1 protein complexed with cholesteryl pullulan (CHP), CHP-NY-ESO-1, and the truncated 146HER2 protein with CHP, CHP-HER2, were subcutaneously administered with the immuno-adjuvant OK-432 to eight esophageal cancer patients. Vaccination was well-tolerated. NY-ESO-1- and HER2-specific antibody responses were analyzed using the patients' sera and samples from previous single CHP-NY-ESO-1 or CHP-HER2 vaccine trial. The responses to NY-ESO-1 in the combination vaccine study were comparable to the single vaccine. For responses to HER2, there were fewer antibody responses in the combination vaccines. Although there were marked individual variations in the antibody responses to the NY-ESO-1 and HER2 antigens, the reaction patterns to these antigens were comparable within each patient. Antibodies to OK-432 were not augmented. Protein cancer vaccines targeting multiple antigens are feasible. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：6854 / 6861

页数：8

共 31 条

[1]

c-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma [J].

Akamatsu, M ;

Matsumoto, T ;

Oka, K ;

Yamasaki, S ;

Sonoue, H ;

Kajiyama, Y ;

Tsurumaru, M ;

Sasai, K .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 57 (05) :1323-1327

[2]

Heterogeneous expression of GAGE, NY-ESO-1, MAGE-A and SSX proteins in esophageal cancer: Implications for immunotherapy [J].

Akcakanat, A ;

Kanda, T ;

Tanabe, T ;

Komukai, S ;

Yajima, K ;

Nakagawa, S ;

Ohashi, M ;

Hatakeyama, K .

INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (01) :123-128

[3]

NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer [J].

Akcakanat, A ;

Kanda, T ;

Koyama, Y ;

Watanabe, M ;

Kimura, E ;

Yoshida, Y ;

Komukai, S ;

Nakagawa, S ;

Odani, S ;

Fujii, H ;

Hatakeyama, K .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2004, 54 (01) :95-100

[4]

HER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival [J].

Dreilich, M. ;

Wanders, A. ;

Brattstrom, D. ;

Bergstrom, S. ;

Hesselius, P. ;

Wagenius, G. ;

Bergqvist, M. .

DISEASES OF THE ESOPHAGUS, 2006, 19 (04) :224-231

[5]

NY-ESO-1 expression and immunogenicity in esophageal cancer [J].

Fujita, S ;

Wada, H ;

Jungbluth, AA ;

Sato, S ;

Nakata, T ;

Noguchi, Y ;

Doki, Y ;

Yasui, M ;

Sugita, Y ;

Yasuda, T ;

Yano, M ;

Ono, T ;

Chen, YT ;

Higashiyama, M ;

Gnjatic, S ;

Old, LJ ;

Nakayama, E ;

Monden, M .

CLINICAL CANCER RESEARCH, 2004, 10 (19) :6551-6558

[6]

Clinically relevant vaccine-vaccine interactions - A guide for practitioners [J].

Gizurarson, S .

BIODRUGS, 1998, 9 (06) :443-453

[7]

Gu XG, 1998, CANCER RES, V58, P3385

[8]

Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma [J].

Gulley, James L. ;

Arlen, Philip M. ;

Tsang, Kwong-Yok ;

Yokokawa, Junko ;

Palena, Claudia ;

Poole, Diane J. ;

Remondo, Cinzia ;

Cereda, Vittore ;

Jones, Jacquin L. ;

Pazdur, Mary P. ;

Higgins, Jack P. ;

Hodge, James W. ;

Steinberg, Seth M. ;

Kotz, Herbert ;

Dahut, William L. ;

Schlom, Jeffrey .

CLINICAL CANCER RESEARCH, 2008, 14 (10) :3060-3069

[9]

Immunohistochemical detection of p53 and c-erbB-2 in oesophageal carcinoma; No correlation with prognosis [J].

Hardwick, RH ;

Barham, CP ;

Ozua, P ;

Newcomb, PV ;

Savage, P ;

Powell, R ;

Rahamin, J ;

Alderson, D .

EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 1997, 23 (01) :30-35

[10]

Presentation of a major histocompatibility complex class 1-binding peptide by monocyte-derived dendritic cells incorporating hydrophobized polysaccharide-truncated HER2 protein complex: implications for a polyvalent immuno-cell therapy [J].

Ikuta, Y ;

Katayama, N ;

Wang, LJ ;

Okugawa, T ;

Takahashi, Y ;

Schmitt, M ;

Gu, XG ;

Watanabe, M ;

Akiyoshi, K ;

Nakamura, H ;

Kuribayashi, K ;

Sunamoto, J ;

Shiku, H .

BLOOD, 2002, 99 (10) :3717-3724

← 1 2 3 4 →